PAM481

REVISIÓN

Avances farmacológicos en la lucha contra la obesidad

Wang L, Wang W, Kaelber DC, Xu R, Berger NA. GLP-1 Receptor Agonists and Colorectal Cancer Risk in Drug-Naive Patients With Type 2 Diabetes, With and Without Overweight/Obesity. JAMA Oncol. 2024; 10(2): 256-8. DOI: 10.1001/ jamaoncol.2023.5573. Wang L, Xu R, Kaelber DC, Berger NA. Glucagon-Like Peptide 1 Receptor Agonists and 13 Obesity-Associated Cancers in Patients With Type 2 Diabetes. JAMA Netw Open. 2024d; 7(7): e2421305. DOI: 10.1001/jamanetwor kopen.2024.21305. Wharton S, Blevins T, Connery L, Rosenstock J, Raha S, Liu R et al . Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity. N Engl J Med. 2023; 389(10): 877-88. DOI: 10.1056/NEJMoa2302392. Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I et al . Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021 Mar 18;384(11):989-1002. DOI: 10.1056/NEJ Moa2032183. Xie Y, Choi T, Al-Aly Z. Mapping the effectiveness and risks of GLP-1 receptor agonists. Nat Med. 2025. DOI: 10.1038/s41591-024-03412-w. Errata en: Nat Med. 2025. DOI: 10.1038/s41591-025 03542-9. Yun C, Yan S, Liao B, Ding Y, Qi X, Zhao M et al . The microbial metabolite agmatine acts as an FXR agonist to promote polycystic ovary syndrome in female mice. Nat Metab. 2024; 6(5): 947-62. DOI: 10.1038/s42255-024-01041-8.

and targets the mesolimbic system. PLoS One. 2015; 10(3): e0119034. DOI: 10.1371/journal. pone.0119034. Rubino D, Abrahamsson N, Davies M, Hesse D, Greenway FL, Jensen C et al . Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021; 325(14): 1414-25. DOI: 10.1001/jama.2021.3224. Rubino DM, Greenway FL, Khalid U, O'Neil PM, Rosenstock J, Sørrig R et al . Effect of Weekly Subcutaneous Semaglutide vs Daily Lira glutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Rando mized Clinical Trial. JAMA. 2022; 327(2): 138-50. DOI: 10.1001/jama.2021.23619. Rubino F, Cummings DE, Eckel RH, Cohen RV, Wilding JPH, Brown WA et al . Definition and diagnostic criteria of clinical obesity. Lancet Dia betes Endocrinol. 2025: S2213-8587(24)00316-4. DOI: 10.1016/S2213-8587(24)00316-4. Sanyal AJ, Kaplan LM, Frias JP, Brouwers B, Wu Q, Thomas MK et al . Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nat Med. 2024; 30(7): 2037-48. DOI: 10.1038/s41591-024-03018-2. Sass F, Ma T, Ekberg JH, Kirigiti M, Ureña MG, Dollet L et al . NK2R control of energy expenditure and feeding to treat metabolic diseases. Nature. 2024; 635(8040): 987-1000. DOI: 10.1038/s41586-024-08207-0. Sohn JW. Network of hypothalamic neurons that control appetite. BMB Rep. 2015; 48(4): 229-33.

DOI: 10.5483/bmbrep.2015.48.4.272. Tyagi P, Patel C, Gibson K, MacDougall F, Pechenov SY, Will S et al . Systems Biology and Peptide Engineering to Overcome Absorption Barriers for Oral Peptide Delivery: Dosage Form Optimization Case Study Preceding Clinical Translation. Pharmaceutics. 2023; 15(10): 2436. DOI: 10.3390/pharmaceutics15102436. Valdecantos MP, Ruiz L, Folgueira C, Rada P, Gomez-Santos B, Solas M et al . The dual GLP-1/glucagon receptor agonist G49 mimics bariatric surgery effects by inducing metabolic rewiring and inter-organ crosstalk. Nat Commun. 2024; 15(1): 10342. DOI: 10.1038/s41467-024 54080-w. Véniant MM, Lu SC, Atangan L, Komorowski R, Stanislaus S, Cheng Y et al . A GIPR anta gonist conjugated to GLP-1 analogues promotes weight loss with improved metabolic parameters in preclinical and phase 1 settings. Nat Metab. 2024; 6(2): 290-303. DOI: 10.1038/s42255-023 00966-w. Wang W, Volkow ND, Berger NA, Davis PB, Kaelber DC, Xu R. Association of semag lutide with reduced incidence and relapse of cannabis use disorder in real-world populations: a retrospective cohort study. Mol Psychiatry. 2024a; 29(8): 2587-98. DOI: 10.1038/s41380 024-02498-5. Wang W, Volkow ND, Wang Q, Berger NA, Davis PB, Kaelber DC et al . Semaglutide and Opioid Overdose Risk in Patients With Type 2 Diabetes and Opioid Use Disorder. JAMA Netw Open. 2024b; 7(9): e2435247. DOI: 10.1001/jama networkopen.2024.35247.

C

M

Y

CM

MY

CY

CMY

K

182